Main Menu
17
Jan
2018

The ICR and Cancer Research UK join forces with leading science and technology company in new drug discovery alliance

Mixture of pills

 Mixture of pills. Image from Pixabay. CC0

Cancer Research UK’s Commercial Partnerships Team and The Institute of Cancer Research, London, announced a multi-project collaboration and licensing deal with Merck, a leading science and technology company, to discover and develop new anticancer drugs, today.

This multi-project deal follows previous single project drug discovery collaborations and a more recent successful target validation collaboration between Merck and Cancer Research UK’s Cancer Therapeutics Unit at the ICR.

The parties will collaborate on three independent research projects spanning target hit discovery to preclinical candidate nomination. This work will progress the discovery and development of potential cancer drugs, as well as develop biomarkers for target engagement and patient selection.

Under the terms of the deal, Merck has worldwide rights to take molecules discovered through the collaboration forward into clinical development. Cancer Research UK and the ICR will receive milestone payments based on the achievement of research and development, regulatory and sales goals plus royalty payments on net sales of future products discovered or developed under the agreement.

Any payments made to Cancer Research UK and ICR will be invested into future lifesaving research.

The ICR's Enterprise Unit has an unrivalled track record at discovering new cancer drugs and medical technologies. This has helped ensure that our research delivers maximum benefit for cancer patients

Find out more

Innovative new treatments

Professor Rajesh Chopra, director of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, said:

“We are delighted to be joining forces with Merck to accelerate the ICR’s world-leading research in understanding cancer pathways, identifying drug targets and discovering cancer drugs.

“We hope that through the diverse projects in this collaboration, we can identify molecules that are effective against a number of different tumour types. Together we can create innovative new treatments for the benefit of patients.”

Dr Iain Foulkes, Cancer Research UK’s executive director of research and innovation, said:

“This collaboration with Merck and one of Cancer Research UK’s major drug discovery units will help accelerate the development of potential new therapies for cancer patients. It is an exciting example of how successful academic networks and the scale of industry can combine to advance scientific and clinical discoveries.

“This latest deal demonstrates Cancer Research UK’s commitment to exploiting the huge number of translational possibilities that arise from our extensive network of world-leading research scientists and clinicians.”

Tags

drug discovery Rajesh Chopra Translational Cancer Discovery
comments powered by Disqus
We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.